VENATORX PHARMACEUTICALS INC — Department of Health and Human Services SBIR Phase I: NIAID
VENATORX PHARMACEUTICALS INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $600,000 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code NIAID links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $600,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- NIAID
- Solicitation
- PA19-272
- NAICS
- —
- Place of performance
- PA
- Period
- 2020-07-15 → 2022-06-30
Description
Ebola viruses (EBOV) cause severe illnesses in humans with a high rate of mortality that approaches 90%. Novel therapies with potent and selective activity against EBOV are urgently needed for the prevention and treatment of Ebola virus disease (EVD). We propose to execute an innovative high throughput screening campaign using a unique reverse genetics system. This screen is expected to yield new inhibitors targeting EBOV replication that will serve as starting points for medicinal chemistry hit-to-lead efforts. If successful, we will deliver one or more new lead series targeting EBOV infection.